Kazia Therapeutics cuts ATM offering to $80M after $5.1M in sales

What happened

Kazia Therapeutics Ltd (NASDAQ: KZIA), a pharmaceutical company, filed a prospectus supplement on August 28, 2026, reducing the maximum aggregate offering price of its American Depositary Shares (ADSs) that may be sold under its existing at-the-market (ATM) facility from $100 million to $80 million. The filing states that the company had already sold 510,000 ADSs for approximately $5.1 million under the facility as of the filing date.

The company's share price fell 16.86% to $14.05 on the day of the filing, with volume of 925,611 shares compared to an average of 195,052, a 4.75x increase. The previous close was $16.90.

The filing

Kazia filed a Form 424B5, which is a prospectus supplement used to update or amend a previously filed registration statement. This supplement amends the prior prospectus dated March 27, 2026, which was part of a Form F-3 registration statement. The purpose is to adjust the maximum offering amount under the Sales Agreement with Leerink Partners LLC, the sales agent.

The supplement notes that the ADSs are listed on the Nasdaq Capital Market under the symbol "KZIA." It also states that Kazia is a "foreign private issuer," which means it follows reduced disclosure requirements under US securities laws.

What this means

An ATM offering is a mechanism that allows a public company to sell new shares gradually over time at prevailing market prices, through a sales agent, rather than in a single fixed-price offering. The company registered up to $100 million of ADSs under this facility, and this supplement reduces the remaining capacity to $80 million, less the $5.1 million already sold. This means the company can still sell roughly $74.9 million more in ADSs, subject to market conditions.

ADSs are American Depositary Shares, which are US-traded securities that represent ownership in foreign company shares. Each ADS here represents 500 ordinary shares of Kazia, a company focused on developing pharmaceutical treatments.

The share price drop likely reflects investor reaction to the potential dilution from future share sales, as the company has not yet sold the full amount and could continue to issue shares. However, the filing does not explain the price decline, and no cause is given in the source materials.